RESUMO
Patients with sports injuries were treated with pirprofen, a non-steroidal anti-inflammatory drug, in two separate studies. In the single centre study, 39 athletes were treated with 1000 mg/day pirprofen for 2 weeks. In the multicentre study, a further 80 athletes were treated with a variable dosage (600-1200 mg/day) until the disappearance of symptoms, but for no longer than 2 weeks. Efficacy was considered excellent or good in 99/119 (83%) of the patients treated. The clinical variables of pain and mobility significantly (P less than 0.05) improved after 1 week of treatment. Tolerability was satisfactory, the main side-effects involving the gastro-intestinal tract.
Assuntos
Anti-Inflamatórios não Esteroides/uso terapêutico , Traumatismos em Atletas/tratamento farmacológico , Dor/tratamento farmacológico , Fenilpropionatos/uso terapêutico , Doença Aguda , Adolescente , Adulto , Traumatismos em Atletas/fisiopatologia , Doença Crônica , Relação Dose-Resposta a Droga , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Movimento , Estudos Multicêntricos como AssuntoRESUMO
A double-blind study was designed to compare the efficacy and tolerability of pirprofen and lysine soluble aspirin administered by iontophoresis to 80 patients with various painful rheumatic diseases. Treatment lasted two weeks, with five administrations a week, each lasting 20 minutes (direct current; mean intensity, 2.3 mA). After five administrations, patients showed significant improvement in pain at rest and on movement, with no significant differences between pirprofen and aspirin. Final results were excellent or good in about 75% of the patients treated and functional improvement was satisfactory in about 80%. There were no side effects.
